MedPath

Xanomeline/Trospium Chloride Shows Cognitive Improvement in Schizophrenia; MindMed's LSD Trial Begins

• Xanomeline/trospium chloride (Cobenfy) improved cognition in schizophrenia patients with baseline cognitive impairment, according to an exploratory analysis of two phase III trials. • MindMed initiated a phase III trial of lysergide D-tartrate (LSD) for generalized anxiety disorder, marking the first phase III trial for LSD. • Reviva Pharmaceuticals reported that brilaroxazine significantly reduced PANSS total score in schizophrenia patients after 52 weeks in a long-term extension study. • A recall of over 230,000 bottles of duloxetine (Cymbalta) was initiated due to the potential presence of a carcinogen.

An exploratory analysis of two phase III trials indicates that xanomeline/trospium chloride (Cobenfy) improved cognition in patients with acute schizophrenia who had clinically significant cognitive impairment at baseline. The findings, published in the American Journal of Psychiatry, suggest a potential therapeutic avenue for addressing cognitive deficits in schizophrenia.

Xanomeline/Trospium Chloride for Cognitive Impairment in Schizophrenia

The study involved patients with acute schizophrenia and clinically significant baseline cognitive impairment. Results showed that xanomeline/trospium chloride led to cognitive improvements in this patient population. These findings highlight the potential of this drug combination to address a critical unmet need in schizophrenia treatment, as cognitive deficits are a major contributor to functional disability.

MindMed's LSD Trial for Generalized Anxiety Disorder

MindMed has announced the commencement of a phase III trial for lysergide D-tartrate (LSD), a pharmaceutically optimized form being investigated as a potential treatment for generalized anxiety disorder (GAD). This marks the first phase III trial for LSD. The Phase IIb findings were previously presented at the American Psychiatric Association annual meeting earlier this year.

Brilaroxazine Shows Promise in Schizophrenia

Reviva Pharmaceuticals announced positive preliminary topline data from the long-term open-label extension portion of the Phase 3 RECOVER study evaluating brilaroxazine in schizophrenia. The strongest dose of once-daily investigational brilaroxazine decreased Positive and Negative Syndrome Scale (PANSS) total score by 20.8 points in patients with schizophrenia at 52 weeks.

Duloxetine (Cymbalta) Recall

Over 230,000 bottles of the antidepressant duloxetine (Cymbalta) have been recalled due to the presence of a potential carcinogen.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

6% of Seniors Depressed; ADHD and Hormones; Novel Antipsychotic Eases Schizophrenia

Recent studies highlight various aspects of mental health, including depression in seniors, the impact of hormones on ADHD symptoms, and the effectiveness of a novel antipsychotic in treating schizophrenia. A study found that 6% of older adults suffer from depression, with higher rates among women, the unmarried, and those with chronic conditions. Another study suggested that ADHD symptoms may fluctuate with hormonal changes. Additionally, a phase II trial showed that a new antipsychotic, LB-102, significantly improved schizophrenia symptoms.

R2D2 Trial Assesses Deprescribing Anticholinergics for Brain Health in Older Adults

The R2D2 trial investigates the impact of deprescribing anticholinergic medications on cognitive function in older adults compared to usual care.
The study employs a cluster randomized design over 24 months, aiming to minimize contamination and detect long-term cognitive changes.

Lumateperone Demonstrates Significant Delay in Schizophrenia Relapse in Phase 3 Trial

Phase 3 trial results show lumateperone 42 mg significantly delays relapse in schizophrenia patients compared to placebo, marking a potential advancement in maintenance therapy.
The study reported a 63% reduction in the risk of relapse with lumateperone compared to placebo (HR, 0.37; 95% CI, 0.22 – 0.65), highlighting its efficacy.

Lumateperone Shows Promise in Preventing Symptomatic Relapse in Schizophrenia

A recent study reveals that lumateperone significantly extends the time to relapse in adults with schizophrenia compared to placebo.
The study demonstrated a 63% reduction in the risk of relapse with lumateperone, highlighting its potential in managing this chronic condition.

Caplyta Shows Positive Phase 3 Results for Schizophrenia Relapse Prevention

Intra-Cellular Therapies' Study 304 demonstrated that lumateperone (Caplyta) significantly extends the time to relapse in schizophrenia patients compared to placebo.
Patients treated with lumateperone experienced a 63% reduction in the risk of relapse versus placebo (HR [95% CI] = 0.37, [0.22, 0.65]).

Lumateperone Augments Antidepressant Therapy in Major Depressive Disorder

Adjunctive lumateperone significantly improved depression symptoms in patients with major depressive disorder who had an inadequate response to prior antidepressants.
The phase III trial demonstrated a statistically significant improvement in MADRS scores with lumateperone compared to placebo by day 8, continuing through day 43.

Lykos Therapeutics' MDMA Therapy for PTSD Faces Potential VA Funding and Third-Party Data Review

Lykos Therapeutics is exploring the possibility of securing funding from the Department of Veterans Affairs (VA) for its Phase 3 clinical trials of MDMA-assisted therapy for PTSD.
As part of its path to FDA approval, Lykos Therapeutics may undergo a third-party review of its Phase 3 data, ensuring an objective assessment of the therapy's efficacy and safety.

Supernus' SPN-820 Shows Promise as Rapid-Onset Depression Treatment

Supernus Pharmaceuticals' SPN-820, a novel mTORC1 modulator, demonstrated safety and efficacy as an adjunctive treatment for major depressive disorder in a Phase IIa trial.
The trial indicated SPN-820's potential for rapid-onset response in adults with depression, addressing a critical need for faster-acting antidepressants.

Obinutuzumab Shows Positive Results in Phase 3 Trial for Lupus Nephritis

Genentech's phase 3 REGENCY trial of obinutuzumab (Gazyva) plus standard therapy met its primary endpoint, demonstrating a statistically significant complete renal response in patients with lupus nephritis.
The study results support the potential of obinutuzumab as a valuable treatment option for lupus nephritis, addressing an unmet need in managing this severe manifestation of systemic lupus erythematosus.

Antidepressant Use for Pain Relief in Seniors Lacks Evidence, Posing Risks

A new review indicates limited evidence supports the use of antidepressants for pain relief in older adults, raising concerns about potential overuse.
Researchers found that seniors using antidepressants for pain had a higher risk of falls, dizziness, and injury compared to those using other methods.

Reference News

[1]
Cymbalta Bottles Recalled; 1 in 3 Older Adults Are Lonely; Walking Off Depression
medpagetoday.com · Dec 18, 2024

Over 230,000 bottles of duloxetine recalled due to potential carcinogen. Xanomeline/trospium chloride improved cognition...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy